Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Apalutamide + Gonadorelin + Radiotherapy |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Apalutamide | Erleada | ARN-509|JNJ-56021927 | Hormone - Anti-androgens 54 | Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov). |
Gonadorelin | Dirigestran|GnRH|LHRHA|AY-24031 | Hormone Antineoplastics 2 | Gonadorelin is a synthetic version of gonatotropin-releasing hormone (GnRH) that binds GnRH receptors and induces gonatotropic hormone release, and leads to down-regulation of GnRH receptor expression and reduced hormone release following sustained exposure (NCI Drug Dictionary). | |
Radiotherapy |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04181203 | Phase III | Gonadorelin + Radiotherapy Apalutamide + Gonadorelin + Radiotherapy | Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2) | Recruiting | FRA | 0 |